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Primary cutaneous CD30-positive large cell lymphoma (CD30+ PCLCL) is a rare subtype of cutaneous T-cell lymphoma (CTCL)
that can present in a variety of ways. We report a patient with a three-month history of an enlarging, exophytic mass with two
smallersatellite lesionson the left forearm.Biopsyof the skinstained positive forCD30, and, after thorough systemicevaluation,a
diagnosisofCD30+PCLCLwasmade.WhenPCLCLissuspected, itisimportanttoperform immunohistologicalstudiesforCD30
types and conduct a thorough workup to rule out systemic LCL. These measures will reduce the use of unnecessarily aggressive
chemotherapy regimens for CD30+ PCLCL, an indolent disease with a favorable prognosis.
1.Introduction
CD30+ PCLCL represents about ten percent of all cases
of cutaneous T-cell lymphomas [1], and it is thought to
represent a spectrum of disease, with lymphomatoid papu-
losis at the benign end, and primary cutaneous anaplastic
large cell lymphoma (PCALCL) at the other [2, 3]. CD30-
positive large cell lymphomas are typically associated with
poor prognosis when they are systemic, though they have
a favorable prognosis when conﬁned to the skin. CD30
expression is a much more important prognostic parameter
than is the extent of skin disease at presentation, as Beljaards
et al. [4] described that 80% of patients with CD30-negative
PCLCL died of progressive disease (median 27 months after
diagnosis) compared to only 7% of patients with CD30+
PCLCL.
2.CasePresentation
An 80-year-old male was seen with a three-month history
of a mass on the left inner forearm that was getting per-
sistently larger and bleeding. Physical examination showed
t h ep r e s e n c eo fa1 0 .0 × 7.0cm exophytic nodule on the
left wrist and forearm. Two smaller satellite nodules were
seen along the mid dorsal forearm, each measuring 2.0 ×
2.0cm(Figure1). No adenopathy was noted. CBC and other
laboratoryvalueswere unremarkable.Abonemarrow biopsy
was performed, and the results were normal. PET scan, CT
scan of the chest and abdomen, and chest X-ray were all
normal. Abiopsy was takenat the time. Itshowed a polypoid
lesion characterized by a dense perivascular and band-like
monomorphous inﬁltrate composed of markedly atypical,
large, pleomorphic epithelioidcells, as well as immature cells
resembling immunoblasts (Figures 2 and 3). Mitoses and
tumor necrosis with accompanying neutrophils were noted.
Reed-Sternberg cells, however, were not observed. Over 75%
oftheatypicallymphoidcellsexpressed CD30(Figure4),but
not ALK1 (Figure 5)a n dE M A( F i g u r e6), which led to the
diagnosis of CD30+ primary cutaneous anaplastic large cell
lymphoma (CD30+ PCLCL). The patient received localized
radiation treatment with excellent results, as the tumor has
completely remitted.
3.Discussion
CD30+ PCLCL usually presents in adults, age 45–60, and
is six-times more frequent in males [5]. It presents as2 ISRN Dermatology
Figure 1: Patient’s left forearm with large exophytic tumor and two
satellite tumors.
Figure 2: H&E staining of the tumor shows a dense perivascular
and band-like monomorphous inﬁltrate composed of markedly
atypical, large, pleomorphic epithelioid cells, along with immature
cells resembling immunoblasts.
Figure 3: H&E staining of the tumor shows a dense perivascular
and band-like monomorphous inﬁltrate composed of markedly
atypical, large, pleomorphic epithelioid cells, along with immature
cells resembling immunoblasts.
Figure 4: Histological image of the tumor stained to show
expression of the CD30 surface marker on the atypical lymphoid
cells.
Figure 5:Histologicalimageofthetumorthatshowsabsenceofthe
ALK-1 protein on the atypical lymphoid cells.
Figure 6:Histologicalimageofthetumorthatshowsabsenceofthe
EMA surface marker on the atypical lymphoid cells.ISRN Dermatology 3
one to several localized nodules or tumors with ulceration.
Twenty percent of cases are multifocal, and the trunk and
extremities are most commonly involved. Plaques are greater
than 1cm in most cases (77%). Draining lymph nodes
are a positive ﬁnding in about 25% of cases. Additional
common features are epidermal ulceration (63%), promi-
nent vascular proliferation (60%), pseudoepitheliomatous
hyperplasia (55%), tumor necrosis (55%), and vascular
inﬁltration by neoplastic cells (44%) [5]. In 20–25% of
cases, Reed-Sternberg-like pleomorphic or immunoblastic
cells are present [6]. Presentation may be variable, with this
lesion being mistaken for other skin disorders, such as adult-
onset eczema, pyoderma gangrenosum, morphea, localized
scleroderma, or squamous cell carcinoma [7].
Histopathologically, dense clusters or nodules of large
CD30+ tumor cells are observed in PCALCL; more than 75
percent of tumor cells should be CD30+ for a diagnosis of
PCALCL. The CD30+ tumor cells are CD4+, and can have
loss of T-cell markers, such as CD2, CD3, and CD5. Cell
surface markers can help in distinguishing PCALCL from
its primary nodal counterpart with secondary cutaneous
disease. The PCALCL tumors more commonly express
HECA-452 and not EMA whereas secondary disease is more
likely to express EMA and not HECA-452 [1]. Systemic
lymphomas are also more likely to contain the t(2;5)
translocation, which creates the fusion protein NPM-ALK
(nucleophosmin-anaplastic lymphoma kinase) [8, 9].
CD30+ anaplastic large cell lymphomas are typically
associated with poor prognosis when they are systemic,
though they have a favorable prognosis when conﬁned to
the skin [4]. The survival rate of CD30+ PCLCL is 95% at
ﬁve years after diagnosis, and about 20% of lesions regress
spontaneously [10]. However, CD30-negative PCLCL is a
much more aggressive neoplasm (though it is indistinguish-
able from CD30+ PCLCL on gross examination), with a
15% 5-year survival [4]. It is crucial to distinguish CD30+
PCLCL from primary nodal LCL with secondary cutaneous
involvement, because patients with secondary skin disease
generallyhaveaworse prognosis andneed tobetreated more
aggressively. The presence of draining lymph nodes does not
seem to alter prognosis. There are no clinical diﬀerences in
presentation, course, or prognosis between anaplastic and
nonanaplastic CD30+ LCL [4].
The standard treatment of single or localized PCALCL
lesions is either local excision or radiation. Chemotherapy
is usually reserved for patients with systemic involvement.
The treatment of patients with only skin and nodal disease
is controversial, with some practitioners favoring radiation
and chemotherapy for these patients [1].
4.Conclusion
Primary cutaneous CD30-positive large T-cell lymphoma
may present in a variety of ways, but is deﬁnitively dis-
tinguished from other cutaneous T-cell lymphomas by the
expression of the CD30 antigen on immunohistological
staining. Other cell surface markers, such as EMA and ALK1
are helpful in distinguishing CD30+ PCLCL from secondary
cutaneous CD30+ LCL, which inﬂuences the prognosis and
decision to add chemotherapy to the treatment regimen.
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